Morgan Stanley analyst Judah Frommer initiated coverage of Evommune (EVMN) with an Overweight rating and $36 price target The firm sees a favorable risk/reward for the shares despite the data for EVO756 and EVO301 being early. Evommune’s “catalyst rich 2026 offers multiple potential opportunities for value inflection,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVMN: